MovDisordV3, Main, Exploration, bibRecordById, pubmed:15593312

Topiramate reduces levodopa‐induced dyskinesia in the MPTP‐lesioned marmoset model of Parkinson's disease

Identifieur interne : 003700 ( Main/Exploration ); précédent : 003699; suivant : 003701

Topiramate reduces levodopa‐induced dyskinesia in the MPTP‐lesioned marmoset model of Parkinson's disease

Auteurs : Monty A. Silverdale [Royaume-Uni] ; S. L. Nicholson [Royaume-Uni] ; A. R. Crossman [Royaume-Uni] ; J. M. Brotchie [Canada]

Source :

Movement Disorders [ 0885-3185 ] ; 2005-04.

RBID : ISTEX:D331B04D6B52D9E2839ED0FFF4E63AD626261F97

Descripteurs français

Pascal (Inist)
- Dyskinésie, Lévodopa, Modèle, Parkinson maladie, Système nerveux pathologie, Topiramate.

English descriptors

KwdEn :
- Animals, Anticonvulsants (therapeutic use), Antiparkinson Agents (administration & dosage), Antiparkinson Agents (therapeutic use), Callithrix, Disease Models, Animal, Dyskinesia, Dyskinesia, Drug-Induced (drug therapy), Dyskinesia, Drug-Induced (etiology), Fructose (analogs & derivatives), Fructose (therapeutic use), Levodopa, Levodopa (administration & dosage), Levodopa (therapeutic use), MPTP, MPTP Poisoning (complications), Models, Nervous system diseases, Parkinson Disease (drug therapy), Parkinson disease, Parkinson's disease, Topiramate, dyskinesia, topiramate.
MESH :
- chemical , administration & dosage : Antiparkinson Agents, Levodopa.
- chemical , analogs & derivatives : Fructose.
- chemical , therapeutic use : Anticonvulsants, Antiparkinson Agents, Fructose, Levodopa.
- complications : MPTP Poisoning.
- drug therapy : Dyskinesia, Drug-Induced, Parkinson Disease.
- etiology : Dyskinesia, Drug-Induced.
- Animals, Callithrix, Disease Models, Animal.

Abstract

Overactive AMPA receptor‐mediated transmission may be involved in the pathogenesis of levodopa‐induced dyskinesia. The mechanism of action of the anticonvulsant drug topiramate involves attenuation of AMPA receptor‐mediated transmission. In this study, the potential antidyskinetic action of topiramate was examined in the MPTP‐lesioned marmoset model of Parkinson's disease and levodopa‐induced dyskinesia. Topiramate significantly reduced levodopa‐induced dyskinesia, without affecting the antiparkinsonian action of levodopa. Topiramate represents an exciting potential novel therapeutic approach to levodopa‐induced dyskinesia in patients with Parkinson's disease. © 2004 Movement Disorder Society

Url:

https://api.istex.fr/document/D331B04D6B52D9E2839ED0FFF4E63AD626261F97/fulltext/pdf

DOI: 10.1002/mds.20345

Affiliations:

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Topiramate reduces levodopa‐induced dyskinesia in the MPTP‐lesioned marmoset model of Parkinson's disease</title>
<author><name sortKey="Silverdale, Monty A" sort="Silverdale, Monty A" uniqKey="Silverdale M" first="Monty A." last="Silverdale">Monty A. Silverdale</name>
</author>
<author><name sortKey="Nicholson, S L" sort="Nicholson, S L" uniqKey="Nicholson S" first="S. L." last="Nicholson">S. L. Nicholson</name>
</author>
<author><name sortKey="Crossman, A R" sort="Crossman, A R" uniqKey="Crossman A" first="A. R." last="Crossman">A. R. Crossman</name>
</author>
<author><name sortKey="Brotchie, J M" sort="Brotchie, J M" uniqKey="Brotchie J" first="J. M." last="Brotchie">J. M. Brotchie</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:D331B04D6B52D9E2839ED0FFF4E63AD626261F97</idno>
<date when="2005" year="2005">2005</date>
<idno type="doi">10.1002/mds.20345</idno>
<idno type="url">https://api.istex.fr/document/D331B04D6B52D9E2839ED0FFF4E63AD626261F97/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">002B91</idno>
<idno type="wicri:Area/Istex/Curation">002B91</idno>
<idno type="wicri:Area/Istex/Checkpoint">002106</idno>
<idno type="wicri:doubleKey">0885-3185:2005:Silverdale M:topiramate:reduces:levodopa</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:15593312</idno>
<idno type="wicri:Area/PubMed/Corpus">003183</idno>
<idno type="wicri:Area/PubMed/Curation">003183</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002F32</idno>
<idno type="wicri:Area/Ncbi/Merge">001118</idno>
<idno type="wicri:Area/Ncbi/Curation">001118</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001118</idno>
<idno type="wicri:doubleKey">0885-3185:2005:Silverdale M:topiramate:reduces:levodopa</idno>
<idno type="wicri:Area/Main/Merge">004D83</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:05-0262059</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001F11</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000E10</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">001C87</idno>
<idno type="wicri:doubleKey">0885-3185:2005:Silverdale M:topiramate:reduces:levodopa</idno>
<idno type="wicri:Area/Main/Merge">005165</idno>
<idno type="wicri:Area/Main/Curation">003700</idno>
<idno type="wicri:Area/Main/Exploration">003700</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Topiramate reduces levodopa‐induced dyskinesia in the MPTP‐lesioned marmoset model of Parkinson's disease</title>
<author><name sortKey="Silverdale, Monty A" sort="Silverdale, Monty A" uniqKey="Silverdale M" first="Monty A." last="Silverdale">Monty A. Silverdale</name>
<affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Department of Neurology, Hope Hospital, Salford, Manchester</wicri:regionArea>
<placeName><settlement type="city">Manchester</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Manchester</region>
</placeName>
</affiliation>
<affiliation wicri:level="4"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Manchester Movement Disorder Laboratory, School of Biological Science, University of Manchester, Manchester</wicri:regionArea>
<placeName><settlement type="city">Manchester</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Manchester</region>
</placeName>
<orgName type="university">Université de Manchester</orgName>
</affiliation>
</author>
<author><name sortKey="Nicholson, S L" sort="Nicholson, S L" uniqKey="Nicholson S" first="S. L." last="Nicholson">S. L. Nicholson</name>
<affiliation wicri:level="4"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Manchester Movement Disorder Laboratory, School of Biological Science, University of Manchester, Manchester</wicri:regionArea>
<placeName><settlement type="city">Manchester</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Manchester</region>
</placeName>
<orgName type="university">Université de Manchester</orgName>
</affiliation>
</author>
<author><name sortKey="Crossman, A R" sort="Crossman, A R" uniqKey="Crossman A" first="A. R." last="Crossman">A. R. Crossman</name>
<affiliation wicri:level="4"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Manchester Movement Disorder Laboratory, School of Biological Science, University of Manchester, Manchester</wicri:regionArea>
<placeName><settlement type="city">Manchester</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Manchester</region>
</placeName>
<orgName type="university">Université de Manchester</orgName>
</affiliation>
<affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Motac Neuroscience Ltd., Williams House, Manchester Science Park, Manchester</wicri:regionArea>
<placeName><settlement type="city">Manchester</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Manchester</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Brotchie, J M" sort="Brotchie, J M" uniqKey="Brotchie J" first="J. M." last="Brotchie">J. M. Brotchie</name>
<affiliation wicri:level="1"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Toronto Western Research Institute, Toronto Western Hospital, Toronto, Ontario</wicri:regionArea>
<wicri:noRegion>Ontario</wicri:noRegion>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2005-04">2005-04</date>
<biblScope unit="vol">20</biblScope>
<biblScope unit="issue">4</biblScope>
<biblScope unit="page" from="403">403</biblScope>
<biblScope unit="page" to="409">409</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">D331B04D6B52D9E2839ED0FFF4E63AD626261F97</idno>
<idno type="DOI">10.1002/mds.20345</idno>
<idno type="ArticleID">MDS20345</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Anticonvulsants (therapeutic use)</term>
<term>Antiparkinson Agents (administration & dosage)</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Callithrix</term>
<term>Disease Models, Animal</term>
<term>Dyskinesia</term>
<term>Dyskinesia, Drug-Induced (drug therapy)</term>
<term>Dyskinesia, Drug-Induced (etiology)</term>
<term>Fructose (analogs & derivatives)</term>
<term>Fructose (therapeutic use)</term>
<term>Levodopa</term>
<term>Levodopa (administration & dosage)</term>
<term>Levodopa (therapeutic use)</term>
<term>MPTP</term>
<term>MPTP Poisoning (complications)</term>
<term>Models</term>
<term>Nervous system diseases</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson disease</term>
<term>Parkinson's disease</term>
<term>Topiramate</term>
<term>dyskinesia</term>
<term>topiramate</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Fructose</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anticonvulsants</term>
<term>Antiparkinson Agents</term>
<term>Fructose</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>MPTP Poisoning</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Dyskinesia, Drug-Induced</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Dyskinesia, Drug-Induced</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Callithrix</term>
<term>Disease Models, Animal</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Dyskinésie</term>
<term>Lévodopa</term>
<term>Modèle</term>
<term>Parkinson maladie</term>
<term>Système nerveux pathologie</term>
<term>Topiramate</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Overactive AMPA receptor‐mediated transmission may be involved in the pathogenesis of levodopa‐induced dyskinesia. The mechanism of action of the anticonvulsant drug topiramate involves attenuation of AMPA receptor‐mediated transmission. In this study, the potential antidyskinetic action of topiramate was examined in the MPTP‐lesioned marmoset model of Parkinson's disease and levodopa‐induced dyskinesia. Topiramate significantly reduced levodopa‐induced dyskinesia, without affecting the antiparkinsonian action of levodopa. Topiramate represents an exciting potential novel therapeutic approach to levodopa‐induced dyskinesia in patients with Parkinson's disease. © 2004 Movement Disorder Society</div>
</front>
</TEI>
<affiliations><list><country><li>Canada</li>
<li>Royaume-Uni</li>
</country>
<region><li>Angleterre</li>
<li>Grand Manchester</li>
</region>
<settlement><li>Manchester</li>
</settlement>
<orgName><li>Université de Manchester</li>
</orgName>
</list>
<tree><country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Silverdale, Monty A" sort="Silverdale, Monty A" uniqKey="Silverdale M" first="Monty A." last="Silverdale">Monty A. Silverdale</name>
</region>
<name sortKey="Crossman, A R" sort="Crossman, A R" uniqKey="Crossman A" first="A. R." last="Crossman">A. R. Crossman</name>
<name sortKey="Crossman, A R" sort="Crossman, A R" uniqKey="Crossman A" first="A. R." last="Crossman">A. R. Crossman</name>
<name sortKey="Nicholson, S L" sort="Nicholson, S L" uniqKey="Nicholson S" first="S. L." last="Nicholson">S. L. Nicholson</name>
<name sortKey="Silverdale, Monty A" sort="Silverdale, Monty A" uniqKey="Silverdale M" first="Monty A." last="Silverdale">Monty A. Silverdale</name>
</country>
<country name="Canada"><noRegion><name sortKey="Brotchie, J M" sort="Brotchie, J M" uniqKey="Brotchie J" first="J. M." last="Brotchie">J. M. Brotchie</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003700 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003700 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:D331B04D6B52D9E2839ED0FFF4E63AD626261F97
   |texte=   Topiramate reduces levodopa‐induced dyskinesia in the MPTP‐lesioned marmoset model of Parkinson's disease
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

Movement Disorders (revue)

Topiramate reduces levodopa‐induced dyskinesia in the MPTP‐lesioned marmoset model of Parkinson's disease

Topiramate reduces levodopa‐induced dyskinesia in the MPTP‐lesioned marmoset model of Parkinson's disease

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.